Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NV › Reno › NPI 1508841990
Lab

Laboratory Corporation of America

Laboratory Corporation of America was paid $518K by Medicaid between Jan 2018 and Jun 2024, across 14 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 81% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA
RENO, NV 89502
33aNPI1508841990assigned 12/08/2005
28Total paid$518K
24GClaims8,326
24DCodes billed14
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#13 of 31
Median peer was paid$269K
This provider vs. median1.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$50K$100K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018744$9K
2019573$3K
20202,974$272K
20211,913$125K
20221,279$86K
2023701$23K
2024incomplete142$281.09
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 81% 4,806 4,521 $421K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 13% 643 637 $70K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.5% 204 202 $13K
86769 1.1% 82 81 $6K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 1,429 1,196 $4K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 90 84 $2K
80053 Comprehensive metabolic panel <1% 378 302 $2K
87529 <1% 12 12 $737.52
85610 <1% 581 405 $729.20
83992 <1% 12 12 $187.20
85730 <1% 14 13 $36.22
82247 <1% 24 13 $23.02
2 more codes
82248 <1% 23 $23.02
36415 Collection of venous blood by venipuncture <1% 28 $10.82

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.